(ENSG) The Ensign - Overview
Stock: Skilled Nursing, Senior Living, Rehabilitative Services, Property Leasing, Ancillary Services
| Risk 5d forecast | |
|---|---|
| Volatility | 24.3% |
| Relative Tail Risk | -8.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.80 |
| Alpha | 58.56 |
| Character TTM | |
|---|---|
| Beta | 0.225 |
| Beta Downside | 0.361 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.49% |
| CAGR/Max DD | 1.48 |
EPS (Earnings per Share)
Revenue
Description: ENSG The Ensign March 01, 2026
The Ensign Group, Inc. (NASDAQ: ENSG) operates a diversified portfolio of senior-care and post-acute facilities across 16 U.S. states, delivering skilled nursing, rehabilitation, and ancillary services such as dialysis and mobile diagnostics. Its business is split between the Skilled Services segment-providing short- and long-term nursing care, specialty therapies, and resident amenities-and the Standard Bearer segment, which owns and leases post-acute care properties to third-party operators.
In the most recent fiscal year (2023), ENSG reported revenue of $1.02 billion, a 7 % year-over-year increase driven by higher occupancy (average 84 % versus 78 % in 2022) and expanded ancillary service lines. The company’s adjusted EBITDA margin rose to 12.5 %, reflecting operational efficiencies from its lease-back model, while its cash flow from operations reached $150 million, supporting ongoing acquisitions and facility upgrades.
Key macro drivers for ENSG include the continued aging of the U.S. population-U.S. Census data projects that adults 65+ will comprise 21 % of the nation by 2030-and favorable Medicare reimbursement trends that have bolstered demand for skilled-nursing and post-acute care beds. Additionally, rising prevalence of chronic conditions such as diabetes and heart disease fuels the need for specialty services like on-site dialysis and cardiac management, areas where ENSG has a growing footprint.
For a deeper quantitative look, consider exploring ENSG’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 344.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.74 > 1.0 |
| NWC/Revenue: 7.47% < 20% (prev 9.72%; Δ -2.25% < -1%) |
| CFO/TA 0.10 > 3% & CFO 564.3m > Net Income 344.0m |
| Net Debt (3.65b) to EBITDA (567.9m): 6.43 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.3m) vs 12m ago 1.21% < -2% |
| Gross Margin: 13.74% > 18% (prev 0.16%; Δ 1359 % > 0.5%) |
| Asset Turnover: 99.84% > 50% (prev 91.24%; Δ 8.59% > 0%) |
| Interest Coverage Ratio: 58.04 > 6 (EBITDA TTM 567.9m / Interest Expense TTM 7.99m) |
Altman Z'' 2.69
| A: 0.07 (Total Current Assets 1.27b - Total Current Liabilities 894.3m) / Total Assets 5.46b |
| B: 0.32 (Retained Earnings 1.76b / Total Assets 5.46b) |
| C: 0.09 (EBIT TTM 463.6m / Avg Total Assets 5.07b) |
| D: 0.54 (Book Value of Equity 1.76b / Total Liabilities 3.23b) |
| Altman-Z'' Score: 2.69 = A |
Beneish M -2.89
| DSRI: 0.94 (Receivables 637.0m/569.9m, Revenue 5.06b/4.26b) |
| GMI: 1.14 (GM 13.74% / 15.67%) |
| AQI: 0.94 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 5.06b / 4.26b) |
| TATA: -0.04 (NI 344.0m - CFO 564.3m) / TA 5.46b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of ENSG shares?
Over the past week, the price has changed by +0.35%, over one month by +22.77%, over three months by +19.12% and over the past year by +64.38%.
Is ENSG a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ENSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 220.4 | 3.4% |
| Analysts Target Price | 220.4 | 3.4% |
ENSG Fundamental Data Overview March 01, 2026
P/E Forward = 28.4091
P/S = 2.4607
P/B = 5.5433
P/EG = 1.8947
Revenue TTM = 5.06b USD
EBIT TTM = 463.6m USD
EBITDA TTM = 567.9m USD
Long Term Debt = 137.5m USD (from longTermDebt, last quarter)
Short Term Debt = 119.0m USD (from shortTermDebt, last quarter)
Debt = 4.15b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.65b USD (from netDebt column, last quarter)
Enterprise Value = 16.03b USD (12.45b + Debt 4.15b - CCE 572.4m)
Interest Coverage Ratio = 58.04 (Ebit TTM 463.6m / Interest Expense TTM 7.99m)
EV/FCF = 43.24x (Enterprise Value 16.03b / FCF TTM 370.7m)
FCF Yield = 2.31% (FCF TTM 370.7m / Enterprise Value 16.03b)
FCF Margin = 7.33% (FCF TTM 370.7m / Revenue TTM 5.06b)
Net Margin = 6.80% (Net Income TTM 344.0m / Revenue TTM 5.06b)
Gross Margin = 13.74% ((Revenue TTM 5.06b - Cost of Revenue TTM 4.36b) / Revenue TTM)
Gross Margin QoQ = 8.67% (prev 14.67%)
Tobins Q-Ratio = 2.93 (Enterprise Value 16.03b / Total Assets 5.46b)
Interest Expense / Debt = 0.05% (Interest Expense 1.96m / Debt 4.15b)
Taxrate = 26.56% (34.5m / 130.1m)
NOPAT = 340.5m (EBIT 463.6m * (1 - 26.56%))
Current Ratio = 1.42 (Total Current Assets 1.27b / Total Current Liabilities 894.3m)
Debt / Equity = 1.86 (Debt 4.15b / totalStockholderEquity, last quarter 2.23b)
Debt / EBITDA = 6.43 (Net Debt 3.65b / EBITDA 567.9m)
Debt / FCF = 9.85 (Net Debt 3.65b / FCF TTM 370.7m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 344.0m / Total Assets 5.46b)
RoE = 16.58% (Net Income TTM 344.0m / Total Stockholder Equity 2.07b)
RoCE = 20.96% (EBIT 463.6m / Capital Employed (Equity 2.07b + L.T.Debt 137.5m))
RoIC = 15.36% (NOPAT 340.5m / Invested Capital 2.22b)
WACC = 5.06% (E(12.45b)/V(16.60b) * Re(6.74%) + D(4.15b)/V(16.60b) * Rd(0.05%) * (1-Tc(0.27)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.50%
[DCF] Terminal Value 86.66% ; FCFF base≈298.0m ; Y1≈308.0m ; Y5≈348.3m
[DCF] Fair Price = 115.3 (EV 10.35b - Net Debt 3.65b = Equity 6.70b / Shares 58.1m; r=5.90% [WACC]; 5y FCF grow 3.44% → 2.90% )
EPS Correlation: 98.15 | EPS CAGR: 17.63% | SUE: 1.39 | # QB: 1
Revenue Correlation: 99.49 | Revenue CAGR: 18.79% | SUE: -1.23 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.84 | Chg7d=+0.063 | Chg30d=+0.068 | Revisions Net=+4 | Analysts=5
EPS current Year (2026-12-31): EPS=7.52 | Chg7d=+0.263 | Chg30d=+0.268 | Revisions Net=+4 | Growth EPS=+14.4% | Growth Revenue=+14.8%
EPS next Year (2027-12-31): EPS=8.24 | Chg7d=+0.227 | Chg30d=+0.228 | Revisions Net=+5 | Growth EPS=+9.6% | Growth Revenue=+9.5%
[Analyst] Revisions Ratio: +1.00 (4 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = +11.6% (Analyst 16.8% - Implied 5.2%)